33.23
price up icon2.50%   0.81
pre-market  プレマーケット:  33.23  
loading
前日終値:
$32.42
開ける:
$32.95
24時間の取引高:
560.64K
Relative Volume:
0.69
時価総額:
$1.89B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
2.9252
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
-6.18%
6か月 パフォーマンス:
-28.71%
1年 パフォーマンス:
+52.92%
1日の値動き範囲:
Value
$32.40
$33.50
1週間の範囲:
Value
$31.39
$35.03
52週間の値動き範囲:
Value
$21.18
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
名前
Agios Pharmaceuticals Inc
Name
セクター
Healthcare (1176)
Name
電話
617-649-8600
Name
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
386
Name
Twitter
@AgiosPharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
AGIO's Discussions on Twitter

AGIO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
33.23 1.89B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-10 再開されました Raymond James Outperform
2024-09-27 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-08 開始されました Cantor Fitzgerald Overweight
2023-02-03 開始されました Piper Sandler Overweight
2022-11-17 アップグレード Goldman Sell → Neutral
2022-07-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-12-03 開始されました BofA Securities Buy
2021-07-30 ダウングレード Goldman Neutral → Sell
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-10 開始されました H.C. Wainwright Buy
2021-03-01 ダウングレード JP Morgan Overweight → Neutral
2021-03-01 アップグレード SVB Leerink Mkt Perform → Outperform
2021-02-26 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-10-22 アップグレード Barclays Equal Weight → Overweight
2020-03-04 開始されました Barclays Equal Weight
2019-11-26 開始されました Cantor Fitzgerald Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-05-23 再開されました Goldman Neutral
2019-02-15 アップグレード SVB Leerink Mkt Perform → Outperform
2018-09-25 開始されました Leerink Partners Mkt Perform
2018-05-23 開始されました Citigroup Buy
2018-04-11 繰り返されました Credit Suisse Outperform
2018-02-15 繰り返されました Needham Buy
2018-02-15 繰り返されました SunTrust Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-08-10 繰り返されました Needham Buy
2017-08-08 繰り返されました SunTrust Buy
2017-08-02 アップグレード Leerink Partners Mkt Perform → Outperform
2017-06-26 ダウングレード Janney Buy → Neutral
2017-01-17 アップグレード Oppenheimer Perform → Outperform
2016-10-24 開始されました Needham Buy
2016-06-13 アップグレード JP Morgan Neutral → Overweight
2016-05-18 繰り返されました SunTrust Buy
すべてを表示

Agios Pharmaceuticals Inc (AGIO) 最新ニュース

pulisher
Jan 20, 2025

Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0% - MarketBeat

Jan 20, 2025
pulisher
Jan 15, 2025

Alpha Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR

Jan 15, 2025
pulisher
Jan 14, 2025

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision (NASDAQ:AGIO) - Seeking Alpha

Jan 14, 2025
pulisher
Jan 13, 2025

Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Insider Monkey

Jan 13, 2025
pulisher
Jan 13, 2025

Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 - MSN

Jan 13, 2025
pulisher
Jan 13, 2025

Agios Pharma Sets Milestones for Rare Disease Growth - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Agios' PYRUKYND Gets FDA Review for Thalassemia Treatment, Major Pipeline Progress for 2025 - StockTitan

Jan 13, 2025
pulisher
Jan 12, 2025

Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey

Jan 12, 2025
pulisher
Jan 12, 2025

The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter

Jan 12, 2025
pulisher
Jan 11, 2025

Agios' supplemental new drug application for its thalassemia treatment gets FDA nod - MSN

Jan 11, 2025
pulisher
Jan 11, 2025

Agios Pharmaceuticals (AGIO-Q) QuotePress Release - The Globe and Mail

Jan 11, 2025
pulisher
Jan 11, 2025

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia - MSN

Jan 11, 2025
pulisher
Jan 10, 2025

Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5%Should You Sell? - MarketBeat

Jan 10, 2025
pulisher
Jan 08, 2025

FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer – Company Announcement - Financial Times

Jan 08, 2025
pulisher
Jan 08, 2025

FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - The Manila Times

Jan 08, 2025
pulisher
Jan 08, 2025

FDA Accepts Agios' PYRUKYND® Application for Thalassemia Treatment Expansion - StockTitan

Jan 08, 2025
pulisher
Jan 07, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Agios Pharmaceuticals executive sells shares worth $90,232 By Investing.com - Investing.com Canada

Jan 07, 2025
pulisher
Jan 07, 2025

Agios Pharmaceuticals executive sells shares worth $90,232 - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

FDA liver injury warning label for Agios' Pyrukynd - The Pharma Letter

Jan 07, 2025
pulisher
Jan 07, 2025

FDA approves label update for Agios's PYRUKYND By Investing.com - Investing.com Australia

Jan 07, 2025
pulisher
Jan 06, 2025

Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

FDA approves label update for Agios’s PYRUKYND By Investing.com - Investing.com Nigeria

Jan 06, 2025
pulisher
Jan 06, 2025

FDA approves label update for Agios's PYRUKYND - Investing.com India

Jan 06, 2025
pulisher
Jan 05, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages - MarketBeat

Jan 05, 2025
pulisher
Jan 04, 2025

JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Jan 04, 2025
pulisher
Jan 03, 2025

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - The Manila Times

Jan 03, 2025
pulisher
Dec 30, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December - MarketBeat

Dec 30, 2024
pulisher
Dec 29, 2024

Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN

Dec 29, 2024
pulisher
Dec 28, 2024

Franklin Resources Inc. Buys Shares of 36,317 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Dec 28, 2024
pulisher
Dec 23, 2024

Objective long/short (AGIO) Report - Stock Traders Daily

Dec 23, 2024
pulisher
Dec 19, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.9%Should You Sell? - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Agios Pharmaceuticals' SWOT analysis: mitapivat potential drives stock outlook - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Agios gains EU orphan drug status for sickle cell treatment By Investing.com - Investing.com UK

Dec 18, 2024
pulisher
Dec 18, 2024

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - The Manila Times

Dec 18, 2024
pulisher
Dec 18, 2024

Agios' Mitapivat Secures Coveted EU Orphan Drug Status for Sickle Cell Disease Treatment - StockTitan

Dec 18, 2024
pulisher
Dec 17, 2024

Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 83 RS Rating - Investor's Business Daily

Dec 17, 2024
pulisher
Dec 16, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% HigherStill a Buy? - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga

Dec 16, 2024
pulisher
Dec 16, 2024

State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Dec 16, 2024

Agios Pharmaceuticals Inc (AGIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):